Our Services
Medical Information
Helpful Resources
Published on: 3/12/2026
There are several factors to consider: depression is biologically diverse, about one-third of people do not respond to a first antidepressant, and medical research volunteers are driving new science by enabling trials of rapid-acting medicines like ketamine-based options, brain stimulation such as TMS, and personalized tools that match treatments to biology.
If your meds are not working, do not stop suddenly and speak with your clinician about dose changes, combinations, or clinical trials; for safety details, practical next steps, and a symptom check that could guide your plan, see below.
Depression is one of the most studied mental health conditions in the world. Yet for many people, antidepressants don't work as well as hoped—or don't work at all. If you feel like your medication isn't helping enough, you're not alone.
According to large clinical studies funded by the National Institute of Mental Health (NIMH), about one-third of people with major depression don't respond to the first antidepressant they try. Some need multiple medication trials. Others continue to experience symptoms despite treatment. This is often called treatment-resistant depression.
So why do depression meds sometimes fail—and what role do medical research volunteers play in finding better solutions?
Let's break it down clearly and honestly.
Antidepressants such as SSRIs (like sertraline or fluoxetine) and SNRIs (like venlafaxine) are backed by strong scientific evidence. They can be life-changing. But depression is complex, and several factors affect treatment success.
Depression is a broad diagnosis. Two people can both have "major depressive disorder" but very different:
Current medications mainly target serotonin, norepinephrine, or dopamine. But depression likely involves many biological systems, not just these neurotransmitters.
Research shows that genetic variations influence:
This helps explain why one medication works well for one person but causes side effects or no improvement for another.
Emerging research suggests that, for some people, depression is linked to chronic inflammation. Traditional antidepressants don't directly target inflammation. That's why scientists are now studying:
These studies depend heavily on medical research volunteers willing to participate in clinical trials.
Most antidepressants take 4–8 weeks to show full effects. During that time:
This delay increases frustration and sometimes leads people to stop treatment early.
Sometimes depression symptoms are worsened by:
Without addressing these, antidepressants alone may not fully help.
If you're currently on antidepressants and want to better understand your symptoms or whether what you're experiencing is typical, Ubie's free AI-powered symptom checker can help you prepare for more informed conversations with your doctor.
If antidepressants don't work for everyone, how does science move forward?
The answer: medical research volunteers.
Every new antidepressant, therapy, or treatment approach exists today because volunteers participated in carefully regulated clinical research.
Medical research volunteers are essential for:
Without volunteers, none of these advances would happen.
Thanks to medical research volunteers, several promising areas are advancing.
Traditional antidepressants take weeks. Newer treatments, such as ketamine-derived medications, can work within hours or days for some patients. Clinical trials made this possible.
Transcranial Magnetic Stimulation (TMS) and other neuromodulation therapies offer non-drug options. These were refined and approved through years of volunteer-driven research.
Researchers are studying:
The goal is to match the right treatment to the right person faster—reducing trial and error.
Under strict medical supervision, compounds like psilocybin are being studied for treatment-resistant depression. Early research shows promise, but these therapies are still under investigation and not widely available outside research settings.
Medical research volunteers make it possible to evaluate safety, dosage, and long-term effects.
This is a common concern.
In the U.S. and many other countries, clinical trials are regulated by:
Volunteers must provide informed consent. They can leave a study at any time.
That said, clinical trials are research. They are not guaranteed treatment. Risks and benefits are carefully explained before participation.
When antidepressants fail, it can feel isolating. But your experience is not wasted data—it may help drive progress.
Medical research volunteers:
Many people participate not only for potential benefit, but to contribute to science.
If you feel your medication isn't helping:
Stopping abruptly can cause withdrawal symptoms and worsening mood.
Note changes in:
Discuss:
If you experience suicidal thoughts, severe mood changes, or dangerous symptoms, seek urgent medical care immediately.
Medication is only one part of depression care. Strong research supports combining medication with:
In many cases, combined treatment works better than medication alone.
Depression medications don't fail because you failed. They sometimes fall short because depression is biologically complex and highly individual.
The good news: science is actively evolving.
Thanks to medical research volunteers, researchers are developing:
Progress depends on people willing to participate in research and on patients who speak openly with their doctors about what is and isn't working.
Most importantly, speak to a doctor about persistent symptoms, medication concerns, or anything that feels serious or life-threatening. Depression is treatable—but treatment sometimes requires adjustment, patience, and partnership with a qualified healthcare professional.
You are not alone. And because of medical research volunteers, better options are continually being developed.
(References)
* Nierenberg AA, Fava M. Treatment-Resistant Depression: A Review of the Current State of Research and Challenges. Clin Ther. 2022 Sep;44(9):1209-1221. doi: 10.1016/j.clinthera.2022.07.009. Epub 2022 Aug 2. PMID: 35926715.
* Zaki H, Al-Ghaithi B, Gopinath B, Zeki M, Quraishi H, Al-Maashari A, Quraishi S. Novel Pharmacological Targets for Treatment-Resistant Depression. Curr Neuropharmacol. 2021 Jan 10;19(1):97-107. doi: 10.2174/1570159X18666200613204739. PMID: 32549221; PMCID: PMC8759560.
* Duman RS, Aghajanian GK, Krystal JH, Sanacora G. Synaptic plasticity and depression: new insights from rapid-acting antidepressants. Nat Med. 2019 May;25(5):697-706. doi: 10.1038/s41591-019-0412-2. PMID: 31065113; PMCID: PMC7201639.
* Trivedi MH, Mayes TL, Claassen CA, Grannemann BD, Eudave D, Carmody TJ. Precision medicine for depression: Current directions and future opportunities. Psychiatr Clin North Am. 2020 Dec;43(4):619-633. doi: 10.1016/j.psc.2020.08.001. PMID: 33203597; PMCID: PMC7771746.
* Vestergaard H, Dalsgaard S, Gøtzsche PC, Jørgensen KJ. Patient experiences of participating in clinical trials for depression: A qualitative study. Patient Educ Couns. 2022 May;105(5):1378-1385. doi: 10.1016/j.pec.2021.10.027. Epub 2021 Oct 27. PMID: 34742583.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.